Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Opioids
The Good, the Bad, and the Ugly
John Fraser
November 22, 2018
“Opioid Crisis”
1. Increase in overdoses and addiction in patients prescribed opioids for chronic pain
2. Increase in overdose deaths in patients with addiction due to high-potency illicit opioids
•Opiate
•Opioid
•Narcotic
Opiate
• Natural substance found in Papaver somniferum (opium poppy)
• Morphine
• Codeine
• Thebaine
Opioid
• Reacts with opioid receptor in the brain
• Semi-synthetic
– Oxycodone (Percocet, Oxycontin)
– Hydromorphone (Dilaudid, Hydromorph contin)
– Heroin
• Synthetic
– Methadone
– Fentanyl
Narcotic
• Psychoactive substance used for non-medical purposes, usually illegal
– Cocaine
– Crystal meth
– Heroin
– Prescription opioids
Morphine
Codeine (Tylenol #3) 1/6
Oxycodone (Percocet, Oxycontin) 1.5
Hydromorphone (Dilaudid, Hydromorph contin) 5
Meperidine (Demerol ) 1/10
Methadone (Metadol) 10
Buprenorphine (Suboxone) 40
Fentanyl (Duragesic ) 80
Carfentanyl 8000
Heroin 5
Opioids
• Opioid – from Greek “opos” meaning “juice”
• 4000 BC - Sumerians
• 3400 BC – Mesopotamia
• 800 AD – traders brought opium to India and China
• 1600 – opioid addiction first described
• 1806 – morphine isolated (Sertürner)– From “Morpheus” – Greek god of dreams
– First active drug purified from a plant sourcePecoraro et al, 2012, Subst Use Misuse
Alam et al. Can J Anaesth. 2016;63:61-8
Helal et al. Eur J Med Chem. 2017;141:632-47
Opioids
• 1810 – addiction defined as a disease (Rush)
• 1874 heroin synthesized (C.R. Wright)
– From “heroisch” – heroic or strong
• 1897 – heroin marketed
– Cough suppressant
– Treatment for morphine addiction
• 1910 – heroin primary illicit drug in USA
• 1924 – heroin banned in USA
Pecoraro et al, 2012, Subst Use Misuse
The GOOD
Sydenham 1680
“Among the remedies which it has pleased Almighty God to give man to relieve his suffering, none is so universal and so efficacious as opium”
Opioids for Pain
• Acute pain
• Cancer pain
• Chronic pain
Chronic Pain in Canada
Region %
Atlantic 22
Quebec 16
Ontario 17
Prairie 20
Alberta 21
British Columbia 22
Canada 19
Chronic Pain in Canada
Schopflocher et al. Pain Res Manage. 2010;16:445-50
Chronic Pain in Canada
Schopflocher et al. Pain Res Manage. 2010;16:445-50
• 23% have pain more than 20 years
• 47% have pain more than 10 years
• 32% pain is severe
Opioids for Chronic Pain
• Cochrane review
• 26 studies, n=4893
• Almost all studies less than 12 weeks
• Weak evidence for long term pain relief
• 33.2% drop out
Noble et al. Cochrane Database Syst Rev. 2010
Opioids for Chronic Pain
• Benefits of opioids roughly equivalent to other pain medications
– Reduction in pain in 11%
– Improvement in function in 10%
• But complications are more common
• Reserved for patients with severe pain that does not respond to other treatments
Physical Therapies
• Physiotherapy
• Chiropractic
• Massage
• Yoga
• Tai Chi
• Acupuncture
• Exercise
Psychological Therapies
• Mindfulness
• Relaxation
• Meditation
• Pain self management group
Drug Therapies
• Anti-inflammatory (ibuprofen, naproxen)
• Acetaminophen
• TCA (amitriptyline, nortriptyline)
• Gabapentin, Pregabalin
• Duloxetine
• Cannabinoids (Nabilone)
• Injections
Opioid Dosing
Past
• Increase the dose until pain is adequately reduced
Present
• Maximum dose of 90 mg morphine for most patients
• Discontinued if there is no significant pain reduction and functional improvement
Complications of Opioid Therapy
The BAD
• Falls
• Sedation
• Mental functioning
• Sleep apnea
• Hyperalgesia
• Depression
• Addiction
• Overdose
The BAD
• Falls twice as many fractures
• Sedation
• Mental functioning poor memory, fuzzy thinking
• Sleep apnea 8 times more common
• Hyperalgesia
• Depression 3 times more common
• Addiction
• Overdose
Addiction Risk in Chronic Pain
• 5.5% overall
• 9% with active addiction
• 8% with active mental illness
• Less than 0.2% with no history of addiction
– About one in 600 patients
Addiction Risk in Chronic Pain
• Systematic review
• 17 studies
• Available evidence suggests that opioid analgesics for chronic pain conditions are not associated with a major risk for developing addiction
Minozzi et al, 2013, Addiction
Addiction Risk in Chronic Pain
• Personal history of addiction
• Family history of addiction
• History of mental illness
• History of childhood trauma
• Age less than 45
Opioid Overdose
Morphine equivalent Overdose death
50 to 200 mg 2 times the risk
over 200 mg 3 times the risk
Gomes et al, 2011, Arch Int Med
USA non-medical use of opioids2001 to 2009
Imtiaz et al, 2014, Subst Abuse Treat Prev Policy
Prescription Opioids in Canada
• Second highest globally
• 23% increase in doses over 200 mg OME from 2006 to 2011
• Proportion of overdose deaths in Ontario caused by prescription opioids rose from 34% in 2002 to 72% in 2012
• 5% population prescribed opioids use them for unintended reasons
Murphy et al. Pain Physician. 2015;18:E605-E614
“Opioid Crisis” #1
How did this happen?
• 1970’s and 80’s
– Pain is undertreated
– Opioid therapy is safe and effective
– Increase the dose as high as needed
• Insufficient education of chronic pain management in medical school and residency
• Prescriber response to patient's suffering
“Opioid Crisis” #1
• Too many patients prescribed opioids
• Opioids prescribed to patients with higher risk
• Opioids prescribed at doses much higher than currently recommended
Resulting in increasing rates of:
• Opioid addiction
• Opioid overdose
“Opioid Crisis” #1
What is the response?
• National Chronic Pain treatment guidelines (2010, 2017)
• Education– Practicing physicians
– Medical school
– Residency
– Public
• Safer opioid formulations
• Prescription Monitoring Programs
The UGLY
Opioid Addictionmillion
Asia 8.1 0.20%
Australasia 0.1 0.46%
Europe 2.1 0.30%
Latin America 1.4 0.25%
North America 1.0 0.30%
North Africa 1.4 0.29%
Sub-Saharan Africa 1.2 0.16%
GLOBAL 15.5 0.22%
Degenhardt et al. Addiction. 2014;109:1320-33
“Opioid Crisis” #2
Heroin, fentanyl, carfentanyl–Very high potency
–Manufactured illicitly
• No pharmaceutical quality control
–Concentration unknown from dose to dose
“Opioid Crisis” #2
This has lead to a very significant increase in overdose deaths in people with opioid addiciton
Addiction
Chronic brain disease
Many factors influencing its development and manifestations
• Genetic
• Environmental
Addiction
Like other chronic diseases, it can be
• Progressive
• Relapsing
• Fatal
Addiction
• Addiction is not a choice
• Starting drug use is a choice
• Stopping drug use is a choice
and
• Starting treatment is a choice
Drugs don’t cause addiction
Addiction develops
in the “at risk” population
in the right setting
with the right drug
Reward Circuit
Frontal cortex
• Problem solving
• Spontaneity
• Initiation
• Judgement
• Impulse control
• Social behaviour
Addiction – The four C’s
•Craving
•Compulsive use
• impaired Control
•Continued use despite harm
Continued Use Despite Harm
• Physical
• Psychological
• Social
• Spiritual
Physical Effects
• HIV 15%
• Hepatitis C 80% (150 times)
Psychological Effects
60 % with mental illness
• Depression
• Anxiety
• Psychosis
Social Effects
• Relationships → family breakup
→ loss of friends
• School → drop out
• Work → unemployment
→ poverty
→ income assistance
Social Effects
• Social life → isolation
→ marginalization
• Housing → substandard
→ homelessness
• Law → DWI
→ crime
Spiritual Effects
• Loss of meaning and purpose
• Loss of relationship with humanity
Opioid Addiction - Halifax
• Age 35 (17 to 72)
• Homeless 27%
• Social assistance 81%
• Injecting 80%
• Hydromorphone (Dilaudid®)
– Acute pain 50 mg
– Chronic pain 90 mg
– Addiction 1160 mg (20 times usual dose)
• Some heroin and fentanyl
Addiction Treatment
• Stages of change
• Motivational interviewing
• Harm reduction
Stages of Change
• Pre-contemplation denial
• Contemplation not ready
• Preparation ambivalent
• Action
• Maintenance relapse
Action
• Patient actively engages in change
• Requires greatest commitment and energy• Repairing broken relationships
• Learning new coping strategies
• Dealing with mental illness (± trauma)
• Filling time
Motivational Interviewing
• Help patient move through stages of change and maintain action
• Change comes from within
• The patient should come up with the arguments for change
(not the worker)
Motivational Interviewing
Change is motivated by a discrepancy between behavior and important goals and values.
“So on the one hand, you tell me that you really want to have a good relationship with your spouse. That is very important to you. But on the other hand, your drug use seems be causing significant problems in your relationship. That’s a pretty difficult situation.”
Harm Reduction
• Respect the decisions people make about their lives
• Provide assistance to maximize their health and reduce harm
Harm Reduction
• Collaboration
• Pragmatism
• Non-judgmental attitude
Non-Judgemental Attitude
• Respect
• Acceptance
• Compassion
• Honesty
• Transparency
• Trust
Harm Reduction
• Self treatment, “cold turkey”
• Community based outreach programs
• Supervised consumption sites
• Needle exchange programs
• Abstinence based programs– Addiction services (detox, group, counselling)
– Residential treatment programs
– 12 step programs (AA, NA)
• Medications
Harm Reduction Strategies
Spectrum of interventions
abstinence methadone needle supervised naloxone ?? exchange consumption
site
Opioid Use Disorder
Harm Reduction • 34 year old woman
• 4 year history of intravenous heroin addiction
• Not interested in stopping
Intervention
• Motivational interviewing to become ready for treatment
• Harm reduction– Naloxone kit
– Needle exchange
– Safe injecting behaviours
– HIV, hepatitis C testing
– Return appointment
Treatment of Opioid Addiction
Abstinence-based treatment
–Detox
–Counselling
–NA
–Residential centres
• Most patients relapse
Treatment of Opioid Addiction
Opioid Agonist Therapy (OAT)• Methadone and buprenorphine (Suboxone®)
• 70% less opioid use
• 90% less overdose deaths
• 50% less HIV transmission
• Significantly less crime
Methadone
• 1937: synthesized in Germany for anlagesia on the front line (never used)
• 1959: first used for addiction by Halliday in Vancouver
• Standard of care
• Once daily oral solution, mixed in Tang®
Buprenorphine
• 1969: first synthesized in the lab
• 1982: first used for opioid addiction in Britain
• Once daily sublingual tablet mixed with naloxone
– Naloxone not absorbed, but if injected causes severe withdrawal
Why Does OAT Work
• Once daily dose
• Effect lasts 24 hours
• Eliminates withdrawal and cravings
• Little euphoric effect
• Blocks euphoric effects of other opioids
• No sedation or cognitive changes
Choice
Methadone Buprenorphine
More patients stayin treatment
Lower risk of overdose
Process of OAT
• Counselling– Peer– Addiction counsellor– Groups
• Advocacy– Housing– Legal issues– Employment
• Other chronic diseases– HIV– Hepatitis C– Mental illness– Chronic pain
Direction 180
admission 6 months
Number using 100% 33%
UDS opioids 88% 15%
Amount used 1160 mg 96 mg
Injections/week 51 <1
Homeless 27% 15%
Sex work 18% 2%
Take Home Doses
• Initially daily witnessed ingestion
• Goal of treatment to normalize life
• Evidence of stability
– No drug use (urine tests)
– Stable, safe housing (safe storage)
– No active mental illness
• Gradual increase from one carry a week to 6
• Taken away at the first sign of instability
Coming off Medication
• Neither planned nor necessary
– Chronic disease
• Predictors of success
– Right reason
– Right time
• 1 year stable
– Right way
• 70% relapse
Summary
• Chronic pain is common (22% in Canada)
• Opioid therapy has limited long term effectiveness but is associated with significant complications
• Opioid therapy is reserved for severe pain when all other treatments have failed
• Opioid therapy should not be prescribed to patients with higher risk
• Opioid dose should be limited to 90 mg morphine for most patients
Summary
• Opioid addiction is a brain disease with severe negative consequences
• Harm reduction is a spectrum of strategies to reduce the harmful effects of drug use
• Opioid agonist therapy (methadone or buprenorphine) is the treatment of choice for opioid addiction
Summary
“Opioid Crisis” #1
• Increase in overdoses and addiction in patients prescribed opioids for chronic pain
• Cause
– Over prescribing of opioids in patients with chronic pain
• Strategies
– National opioid prescribing guidelines
– Education
– Prescription monitoring programs
Summary
“Opioid Crisis” #2
• Increase in overdose deaths in patients with addiction due to high-potency illicit opioids
• Cause
– Very potent non-pharmaceutical opioids with unpredictable concentrations (fentanyl, carfnetanyl)
• Strategies: harm reduction
– Naloxone
– Supervised injection sites
– Opioid agonist therapy
Questions